COLL News and Press, Collegium Pharmaceutical Inc. From 04/07/22

STOUGHTON, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in the following investor conference: 21 st Annual Needham Vi...

Collegium Pharmaceutical Inc. (NASDAQ:COLL) traded at a new 52-week high today of $29.65. So far today approximately 37.9 million shares have been exchanged, as compared to an average 30-day volume of 403,000 shares. Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It ...

STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. “Collegium i...

Collegium Pharmaceutical (NASDAQ:COLL) initiates annual guidance to account for the impact of recent acquisition of BioDelivery Sciences International. The specialty pharmaceutical company stated Tuesday it expects Collegium's FY22 product revenues to range between $450-$465M, reflecting grow...

– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA Expected in the Range of $235.0 million to ...

STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in t...

Berkshire Hathaway to acquire all outstanding Alleghany shares for $848.02 per share in cash, for a total equity value of approximately $11.6 billion. This is one of the five largest acquisitions in Berkshire's history and it ends Buffett's six-year drought of large acquisitions. ...

Pharma/biotech is undervalued by about 14% relative to 11-year averages. Life science tools and healthcare equipment are overvalued by over 25%. Focus on IXJ: a more diversified alternative to XLV. 10 stocks cheaper than their peers in March. For further details see: ...

SA readers gravitated to extremes last week, taking notice of both smaller newsmakers and megacap safe havens. The dynamic came as investors looked for potential winners in an uncertain market that saw stocks whipsawed by the conflict in Ukraine. According to an analysis of portfolio addition...

Collegium Pharmaceutical, Inc. (COLL) Q4 2021 Earnings Conference Call February 24, 2022, 04:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations & Corporate Communications Joe Ciaffoni - President, CEO & Director Colleen Tupper - CFO Scott Dreyer - Chief Commercial...